Hemophilia Treatment Market - by Product (Recombinant coagulation factor concentrates, Plasma derived coagulation factor concentrates, Antifibrinolytic agents, and Desmopressin), by Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : Jul 2018 |
  • Pages : 165 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Hemophilia Treatment Market – Treatment for Group of Genetic Bleeding Disorders

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factors. There are around 13 types of clotting factors that work with blood platelets to help the clotting. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in factor VIII. Hemophilia B occurs due to deficiency of factor IX and Hemophilia C is caused due to factor XI deficiency. Although Hemophilia is incurable, it can be treated to reduce symptoms and avoid future health complications. Its treatment involves management of bleeding episodes, treatment and rehabilitation of hemophilia synovitis, treatment of factor VIII (FVIII) inhibitors, and prophylaxis.

The global hemophilia treatment market size was valued at US$ 9,412.1 million in 2017 and is expected to witness a robust CAGR of 4.2% over the forecast period (2018 - 2026).

Figure 1. Global Hemophilia Treatment Market (US$ Mn), by Region, 2017

hemophilia treatment market

Increasing incidences of hemophilia worldwide is projected to drive market growth over the forecast period

High prevalence of hemophilia is propelling demand for its treatment, which is projected to drive market growth over the forecast period. According to the National Hemophilia Foundation 2018, hemophilia affected more than 400,000 individuals. Furthermore, an estimated 75% of patients suffering from hemophilia have no access to treatment or receive inadequate treatment. Moreover, according to Center for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is nearly four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.

According to CDC funded randomized clinical trial, children treated on timely basis to prevent bleeding have less indication of joint damage by age of 6 years. Around 70% hemophilia patients in the U.S. receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers. High-cost associated with recombinant products, serious adverse effects associated with plasma derived products, and limited access to treatment can negatively affect the growth of the global hemophilia market. For instance, risk of infectious disease transmission with plasma derived products can complicate the disease treatment.

Advancing medical knowledge and scientific research to accelerate the market growth

Rise in funding for R&D and advancement in diagnostic technology are expected to prove another booming factor for hemophilia treatment market growth. National Hemophilia Foundation (NHF) award fellowships and grants to support advanced research aimed at finding better cures and treatments for hemophilia. The organization also supports increased federal funding for research and development. Furthermore, gene therapy promises of treating genetic disorders by delivering a functional DNA copy, generally using viral vectors. Many research organizations and biotechnology companies in the gene therapy field are targeting hemophilia for development of advanced treatment options, as it can significantly reduce costs for healthcare providers and patients. Many biotechnology companies are competing to introduce the gene therapy for hemophilia. Spark Therapeutics (U.S.) and uniQure (Netherlands) have the most advanced programs so far.

The major players operating the global hemophilia treatment market include Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer, Inc., Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.

Hemophilia is a genetic disorder in which patient’s blood do not clot normally due to lack of blood-clotting proteins. Hemophilia treatment mainly depends on its severity. The treatment includes timely replacement of the specific clotting factor. Increasing number of hemophilic patient requiring treatment and increased diagnosis rate for Hemophilia are major factors anticipated to drive market growth.

Market Dynamics

The major factors driving growth of the Hemophilia treatment market is increasing diagnosis rate. In the U.S., majority of Hemophilia cases are diagnosed at a very young age. According to CDC, the median age for diagnosis is one month for individuals with severe symptoms, 8 months for individuals with moderate Hemophilia, and 36 months for people with mild Hemophilia. Hemophilia treatment is more costly and less effective in 25% of individuals with severe type A disease and in the three percent of individuals with severe type B disease who produce neutralizing inhibitors against factor VIII and factor IX, respectively. Various ongoing treatments such as gene therapy can significantly improve the quality of life for Hemophilia patients by eradicating frequent hospital visits and infusions and shifting patients from severe to mild Hemophilia. Increasing R&D investments and product innovations by many industry players is expected to drive growth of the market over the forecast period. For instance, in 2016, FDA approved Bayer’s Kovaltry drug, a low-frequency dosage for Hemophilia A, which requires two to three doses per week.

Key features of the study:

  • This report provides in-depth analysis of Hemophilia treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global Hemophilia treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer, Inc., Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global Hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Hemophilia treatment market

Detailed Segmentation:

  • Global Hemophilia Treatment Market, By Product Type:
    • Recombinant coagulation factor
    • Plasma derived coagulation factor
    • Antifibrinolytic agents
    • Desmopressin
  • Global Hemophilia Treatment Market, By Disease Type:
    • Hemophilia A
    • Hemophilia B
    • Hemophilia C
  • Global Hemophilia Treatment Market, By Geography:
    • North America
      • By Product Type:
        • Recombinant coagulation factor concentrates
        • Plasma derived coagulation factor concentrates
        • Antifibrinolytic agents
        • Desmopressin
      • By Disease Type:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Recombinant coagulation factor concentrates
        • Plasma derived coagulation factor concentrates
        • Antifibrinolytic agents
        • Desmopressin
      • By Disease Type:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Recombinant coagulation factor concentrates
        • Plasma derived coagulation factor concentrates
        • Antifibrinolytic agents
        • Desmopressin
      • By Disease Type:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Recombinant coagulation factor concentrates
        • Plasma derived coagulation factor concentrates
        • Antifibrinolytic agents
        • Desmopressin
      • By Disease Type:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Recombinant coagulation factor concentrates
        • Plasma derived coagulation factor concentrates
        • Antifibrinolytic agents
        • Desmopressin
      • By Disease Type:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Recombinant coagulation factor concentrates
        • Plasma derived coagulation factor concentrates
        • Antifibrinolytic agents
        • Desmopressin
      • By Disease Type:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Baxalta *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Market Strategies
    • Baxter International, Inc.
    • Biogen Idec, Inc.
    • Bayer AG
    • CSL Behring
    • Chugai Pharmaceutical Co.
    • Ferring B.V.
    • Genentech, Inc.
    • Hospira, Inc.
    • Kedrion
    • Novo Nordisk
    • Octapharma AG
    • Pfizer, Inc.
    • Sanofi SA
    • Shire Plc.
    • Swedish Orphan Biovitrum AB

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Disease Type
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Key Highlights
    • New Therapy Developments
    • Regulatory Scenario
    • Regulatory Guidelines
  4. Global Hemophilia Treatment Market, By Product Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Recombinant coagulation factor concentrates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Plasma derived coagulation factor concentrates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Antifibrinolytic agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Desmopressin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Hemophilia Treatment Market, By Disease Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hemophilia A
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Hemophilia B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Hemophilia C
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Hemophilia Treatment Market, By Region, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 – 2026
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Disease Type, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Baxalta*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Baxter International, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Biogen Idec, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • CSL Behring
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Chugai Pharmaceutical Co.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Ferring B.V.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Genentech, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Hospira, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Kedrion
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Novo Nordisk
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Octapharma AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Shire Plc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Swedish Orphan Biovitrum AB
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 25 figures on "Global Hemophilia Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.